Company Overview: ADMA Biologics

Industry News

9 Dec

ADMA Biologics Expands Commercial Operations Team in Preparation for Commercial Launch of RI-002 in Second Half of 2016

RAMSEY, N.J., Dec. 09, 2015 (GLOBE NEWSWIRE) — ADMA Biologics, Inc. (ADMA), announced today the expansion of its commercial operations team, appointing Alan Erck as the Company’s Vice President, Sales and National Accounts. ADMA Biologics is a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based...

Read more

3 Dec

ADMA Biologics to Present at the Oppenheimer 26th Annual Healthcare Conference

RAMSEY, N.J., Dec. 03, 2015 (GLOBE NEWSWIRE) — ADMA Biologics, Inc. (ADMA), a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, today announced it is scheduled to present at the Oppenheimer 26th Annual Healthcare Conference at...

Read more

26 Jul

ADMA Biologics, Inc

ADMA is a specialty immune globulin company that develops, manufactures and intends to market plasma-based biologics targeted to niche patient populations for the treatment and prevention of certain infectious diseases. The Company’s target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease or who may...

Read more

Enter your email address to receive notifications of new posts by email.

Latest Tweets

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address